- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06001268
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS) (STRONG-PCS)
March 31, 2026 updated by: H. Lee Moffitt Cancer Center and Research Institute
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Pancreatic Cancer Undergoing Surgery (STRONG-PCS)
The purpose of the study is to assess the feasibility and participant satisfaction with the Support through Remote Observation and Nutrition Guidance program.
The program provides enhanced dietician access and nutrition support for participants living with pancreatic cancer who are undergoing surgery.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emma Hume
- Phone Number: 813-745-6426
- Email: Emma.Hume@moffitt.org
Study Contact Backup
- Name: Kea L Turner, PhD
- Phone Number: 813-745-5213
- Email: Kea.Turner@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Emma Hume
- Phone Number: 813-745-6426
- Email: Emma.Hume@moffitt.org
-
Principal Investigator:
- Kea L Turner, PhD, MPH, MA
-
Principal Investigator:
- Pamela J Hodul, MD
-
Sub-Investigator:
- Amir Alishahi Tabriz, MD, PhD, MPH
-
Sub-Investigator:
- Brian D Gonzalez, PhD
-
Sub-Investigator:
- Nate H Parker, MPH, PhD
-
Sub-Investigator:
- Laurence R Gore, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ≥18 years old
- Diagnosis of pancreatic cancer
- Completed open pancreatic surgery (e.g., Whipple, distal/subtotal pancreatectomy, total pancreatectomy) for treatment at Moffitt Cancer Center
- Discharged on an oral diet
- Able to speak and read English or Spanish
- Able to provide informed consent
Exclusion Criteria:
- Determined to be ineligible for surgery during evaluation (e.g., cancer metastasis)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: STRONG-PCS Intervention
Participants will receive an initial in-person consultation with a dietician within 2 weeks of hospital discharge.
Then participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing their data with a dietician.
|
Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.
Participants will take a survey at baseline and weeks 4,8,& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days.
This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much.
A higher total score indicates better quality of life.
|
|
Active Comparator: Usual Care
Participants will be referred for nutrition counseling from a dietitian based on clinical discretion.
|
Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.
Participants will take a survey at baseline and weeks 4,8,& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days.
This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much.
A higher total score indicates better quality of life.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment Rate - Feasibility
Time Frame: Up to 48 months
|
The study will be deemed feasible if ≥ 50% of eligible participants are enrolled.
|
Up to 48 months
|
|
Retention Rate - Feasibility
Time Frame: at 8 weeks
|
The study will be deemed feasible if ≥ 70% of participants enrolled at baseline will be retained at 8 weeks.
|
at 8 weeks
|
|
Data Collection - Feasibility
Time Frame: at 8 weeks
|
The study will be deemed feasible if ≥ 70% of participants log food for greater than 80% of study days.
|
at 8 weeks
|
|
Participant Satisfaction - Acceptability
Time Frame: at 8 weeks
|
The study will be deemed acceptable if ≥ 70% of participants rate the overall intervention as satisfactory using a validated 4-item scale (score range 0-20, score >/= 12).
|
at 8 weeks
|
|
Participant Rating on Ease of Use the Mobile Application - Usability
Time Frame: at 8 weeks
|
The study will be deemed usable if ≥ 60% of participants rate the mobile application as easy-to-use for logging dietary intake using a validated 10-item scale (score range from 0-100, score of >/=60).
|
at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Malnutrition-Significant weight loss
Time Frame: 90 days
|
Significant weight loss is defined as >5% and >10% of body weight at 30, 60, and 90 days after discharge.
This will be calculated based on weight obtained during clinic visits.
|
90 days
|
|
Malnutrition - Low BMI
Time Frame: at Baseline, 30, 60 and 90 days
|
Low BMI will be defined as <20kg/m² for individuals <70 years old and <22kg/m2 for individuals ≥70 years old.
This will be calculated based on weight and height measurements from clinic visits.
|
at Baseline, 30, 60 and 90 days
|
|
Malnutrition - Low Skeletal Muscle Mass
Time Frame: At baseline, 30, 60 and 90 days
|
Low muscle mass will be estimated by calculating skeletal muscle index (SMI) from routinely collected CT scans at baseline and 90 days after discharge (CT scans are conducted every 3 months).
Low muscle mass will be defined as SMI ≤38.9 cm2 /m2 for females and SMI ≤55.4 cm2 /m2 for males.
|
At baseline, 30, 60 and 90 days
|
|
Quality of Life
Time Frame: at Baseline, 4, 8 and 12 weeks
|
Quality of Life will be measured using the Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about the participant's physical, social, emotional and functional well being over the past 7 days.
This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much.
A higher score indicates a better quality of life.
|
at Baseline, 4, 8 and 12 weeks
|
|
Hospital Readmissions
Time Frame: 30, 60 and 90 days post-hospital discharge
|
Hospital readmissions will be measured using a self-reported survey item to determine whether the patient was admitted to the index hospital or another hospital after hospital discharge.
|
30, 60 and 90 days post-hospital discharge
|
|
Malnutrition -Nutritional Status
Time Frame: at Baseline, 30, 60 and 90 days
|
Nutritional status will be measured using the Patient-Generated Subjective Global Assessment (PG-SGA) Short Form (score range: 0-35) and categorized based on a prior validation study (0-1 well nourished, 2-8 at-risk, = 9 severely malnourished).
|
at Baseline, 30, 60 and 90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Kea Turner, PhD, Moffitt Cancer Center
- Principal Investigator: Pamela J Hodul, MD, Moffitt Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2023
Primary Completion (Estimated)
August 1, 2027
Study Completion (Estimated)
August 1, 2027
Study Registration Dates
First Submitted
August 14, 2023
First Submitted That Met QC Criteria
August 18, 2023
First Posted (Actual)
August 21, 2023
Study Record Updates
Last Update Posted (Actual)
April 1, 2026
Last Update Submitted That Met QC Criteria
March 31, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Neoplasms by Site
- Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Surveys and Questionnaires
Other Study ID Numbers
- MCC-22476
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsUnited States, Japan, South Korea
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...Peking University Cancer Hospital & InstituteNot yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis Pharmaceuticals; Huntsman Cancer InstituteTerminatedMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
Clinical Trials on Fitbit Data Collection
-
Tokyo UniversityGoogle LLC.CompletedCognitive Function | MCI | Cognition Disorders in Old Age | Frailty/SarcopeniaJapan
-
NYU Langone HealthWithdrawnSevere Sleep Apnea | Severe Insomnia | Epileptiform ActivityUnited States
-
Care Management PlusCompletedHealth Information Technology | Nurse Based Care ManagementUnited States
-
University Hospital, Basel, SwitzerlandRecruitingInfections With CPBSwitzerland
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingGastroEsophageal CancerUnited States
-
M.D. Anderson Cancer CenterUnknownPediatric CancerUnited States
-
GlaxoSmithKlineCompletedInfections, StreptococcalRomania, Slovenia, Poland, Lithuania, Estonia
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinCompleted
-
GCS Ramsay Santé pour l'Enseignement et la RechercheCompleted
-
Xuanwu Hospital, BeijingRecruitingMultiple Sclerosis | Myasthenia Gravis | Autoimmune Encephalitis | Acute Disseminated Encephalomyelitis | NMO Spectrum Disorder | Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseChina